NeuroPace (NASDAQ:NPCE) Shares Down 4.3% - Should You Sell?

NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report)'s share price was down 4.3% on Friday . The stock traded as low as $11.78 and last traded at $11.85. Approximately 168,073 shares changed hands during mid-day trading, an increase of 30% from the average daily volume of 128,856 shares. The stock had previously closed at $12.38.

Analyst Ratings Changes

Several equities research analysts have commented on NPCE shares. UBS Group began coverage on NeuroPace in a report on Tuesday, January 21st. They issued a "buy" rating and a $17.00 target price on the stock. Wells Fargo & Company raised their target price on shares of NeuroPace from $13.00 to $17.00 and gave the stock an "overweight" rating in a report on Thursday, January 30th. Cantor Fitzgerald upped their price target on shares of NeuroPace from $19.00 to $20.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of NeuroPace from $9.00 to $14.00 and gave the company an "overweight" rating in a research report on Tuesday, December 17th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, NeuroPace presently has an average rating of "Moderate Buy" and a consensus price target of $15.20.

NeuroPace Stock Performance

The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. The business's fifty day simple moving average is $12.63 and its 200-day simple moving average is $10.35. The firm has a market capitalization of $440.86 million, a PE ratio of -13.54 and a beta of 2.06.

Remove Ads

NeuroPace (NASDAQ:NPCE - Get Free Report) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.07. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The company had revenue of $21.47 million during the quarter, compared to analyst estimates of $21.14 million. As a group, equities research analysts expect that NeuroPace, Inc. will post -1 EPS for the current year.

Insiders Place Their Bets

In other NeuroPace news, insider Martha Morrell sold 3,200 shares of the business's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $15.01, for a total transaction of $48,032.00. Following the transaction, the insider now owns 87,062 shares in the company, valued at $1,306,800.62. The trade was a 3.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Ltd. Kck sold 5,270,845 shares of the stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $9.40, for a total transaction of $49,545,943.00. The disclosure for this sale can be found here. Insiders sold 5,352,479 shares of company stock valued at $50,670,217 in the last three months. Corporate insiders own 22.20% of the company's stock.

Institutional Investors Weigh In On NeuroPace

Institutional investors and hedge funds have recently modified their holdings of the business. State Street Corp lifted its position in shares of NeuroPace by 9.1% during the third quarter. State Street Corp now owns 155,490 shares of the company's stock worth $1,084,000 after purchasing an additional 12,912 shares during the last quarter. Barclays PLC lifted its holdings in NeuroPace by 346.0% during the 3rd quarter. Barclays PLC now owns 20,633 shares of the company's stock valued at $144,000 after buying an additional 16,007 shares in the last quarter. Geode Capital Management LLC boosted its position in NeuroPace by 8.7% in the 3rd quarter. Geode Capital Management LLC now owns 317,192 shares of the company's stock valued at $2,211,000 after buying an additional 25,330 shares during the period. JPMorgan Chase & Co. grew its stake in NeuroPace by 106.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company's stock worth $84,000 after acquiring an additional 6,181 shares in the last quarter. Finally, KCK LTD. purchased a new stake in shares of NeuroPace in the fourth quarter valued at approximately $58,981,000. 78.83% of the stock is owned by institutional investors.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.